Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month high of $61.90. The stock has a fifty day moving average price of $12.49 and a 200-day moving average price of $26.68. Corbus ...

Corbus Pharmaceuticals has a 52 week low of $9.11 and a 52 week high of $61.90. The stock has a market cap of $119.11 million, a P/E ratio of -2.09 and a beta of 2.63. Institutional Inflows and ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study ...

NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the ...

NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human ...

In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $75.00. The company’s ...

Corbus Pharmaceuticals Holdings, Inc. has announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701 (SYS6002), which targets Nectin-4 in patients with ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.22% to $8.78 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial ...

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced on Tuesday that it will present updated data from its Phase 1 dose escalation study of CRB-701 or SYS6002 at the 2025 American ...